All In Biotech

Drug Trial Radar · NCT00548379

Kabul Vitamin D Supplementation Trial

The Effect of Vitamin D Supplementation on the Incidence of Pneumonia in Children in Afghanistan: a Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: May 16, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,048 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,048

Actual

Start

Nov 2007

Primary completion

Jun 2009

Study completion Jul 2009

Sponsor

Lead sponsor
London School of Hygiene and Tropical MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wellcome Trust; Aga Khan Health Services; Aga Khan University; Maywand Hospital, Kabul
First posted
Oct 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 1 month, up to 11 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: Pneumonia is the leading cause of childhood mortality, accounting for 19% of the 10.6 million deaths that occur each year1. Case-control studies from Ethiopia2 and India3 suggest that sub-clinical vitamin D deficiency may increase ten times the risk of pneumonia in children. We postulate that controlling childhood vitamin D deficiency has the potential to dramatically reduce the incidence of pneumonia and save \>700,000 lives each year since vitamin D deficiency is widespread in developing countries. Aim: To investigate whether 3-monthly oral supplementation of 100,000iu vitamin D reduces pneumonia and its consequences among children aged 1-12 months (followed for 18 months), living in a deprived area of Kabul, Afghanistan, where \>70% of young children are vitamin D deficient (\<8ng/dl). The effect of vitamin D on the incidence of other diseases, in particular diarrhea and rickets will also be investigated. Methods: Randomised double-blind placebo-controlled trial: 3000 children will be randomised to receive either 6 doses of vitamin D or placebo. The first dose will be given at the start of autumn and the second and subsequent doses every 3 months thereafter; children will be followed for 18 months. Incidence of pneumonia will be ascertained though weekly home visits (active surveillance) and from attendances and admissions at the trial clinic and wards in the hospital serving the study area (passive surveillance).

Conditions

  • Pneumonia
  • Vitamin D Deficiency

Interventions

  • vitamin DDrug

    vitamin D 100,000 units once in 3 months

  • placeboDrug

    olive oil 1ml

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of pneumoniaTime frame: 18 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Maywand Hospital

    Kabul, Afghanistan

  • Aga Khan Health Services

    Kabul, Kabul, Afghanistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.